Alpha-Synuclein / SNCA (A30P/A53T Mutant) Human Protein

CAT#: SA6003

Alpha-Synuclein / SNCA (A30P/A53T Mutant) human recombinant protein, 0.1 mg

Product Images

Specifications

Product Data

• Species: Human
• Expression Host: E. coli
• Expression cDNA Clone or AA Sequence: MDVFMKGLSK AKEGVVAAAE KTKQGVAEAP GKTKEGVLYV GSKTKEGVVH GVTTVAEKTK EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEPEA
• Predicted MW: 14.516 kDa
• Purity: >95% by SDS-PAGE
• Buffer: Presentation State: Purified
  State: Liquid protein
  Buffer System: 20 mM Tris-HCl buffer (pH 7.5) containing 0.1 M NaCl
• Preparation: Liquid protein
• Protein Description: A Parkinson's disease-related double mutant (A30P/A53T) of α-synuclein. The recombinant protein was purified to apparent homogeneity by taking advantage of the thermosolubility of the protein and by using conventional column chromatography techniques.
• Note: Real molecular weight on SDS-PAGE will be shift up (see picture below).
• Storage: Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C. Avoid repeated freezing and thawing.
• Stability: Shelf life: one year from despatch.

Reference Data

• RefSeq: NP_000336
• Locus ID: 6622
• Cytogenetics: 4q22.1
• Synonyms: NACP; PARK1; PARK4; PD1
• Summary: 'Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Alternatively spliced transcripts encoding different isoforms have been identified for this gene. [provided by RefSeq, Feb 2016]'
• Protein Families: Druggable Genome
• Protein Pathways: Alzheimer's disease, Parkinson's disease